Abstract Tissue transglutaminase 2 (TG2) is involved in many biological processes, from wound healing to neurodegeneration. Recently, there has been an increasing interest in this enzyme as a potential prognostic marker or therapy target in human neoplasms. The aim of this study was to analyze expression of TG2 messenger RNA (mRNA) and protein in colon cancer samples and to evaluate the potential value of TG2 as prognostic marker. We investigated not only expression level but also location of the protein in a series of human tumors. In silico analysis using the GSE39582 dataset showed that TG2 mRNA expression is associated with earlier relapse. The results of qPCR in our cohort showed TG2 mRNA to be upregulated in 25 out of 70 samples (34 %). Kaplan-Meier plots and log-rank test showed that patients with high TG2 mRNA expression have significantly worse prognosis in terms of overall survival (OS) and a trend to earlier recurrence. Immunohistochemical staining of tumor sections for TG2 revealed stromal staining in 152 cases (88 %) and epithelial cell staining in 105 cases (62 %). In stage II patients, stromal expression showed a significant association with disease-free survival (DFS). In patients with metastatic disease, TG2 expression was also associated with poor prognosis. Cox multivariate analysis showed that TG2 expression in epithelial cells is significantly and independently associated with OS, together with node involvement and presence of metastasis. Stromal TG2 expression was associated with DFS. In summary, in non-metastatic colorectal cancer patients, stromal TG2 expression is significantly associated with DFS and epithelial TG2 expression with OS, independently of node involvement and metastasis.
Introduction
Transglutaminase 2 (TG2) is a member of the transglutaminase family, also called tissue transglutaminase. TG2, encoded by a stress-responsive gene, is a transcriptional target of hypoxiainducible factor (HIF-1α) [1] . TG2 is a calcium-dependent multifunctional protein-cross-linking enzyme and a dual function G protein [2] . Although the diverse biological activities of TG2 are mainly modulated by calcium, other factors like GTP or the redox potential can regulate its function [3] .
TG2 is up-regulated in wound healing [4] [5] [6] [7] and has been implicated in the pathogenesis associated to fibrogenic reactions in various organs [8] . It catalyzes cross-linking of extracellular matrix proteins and regulates extracellular matrix (ECM) stability and is involved in maintenance of the cytoskeleton [9] . TG2 associates with members of the integrin family to promote stable interactions between cells and the ECM, resulting in increased cell survival, migration, and invasion [10] [11] [12] .
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TG2 is strongly expressed in tumor tissue of various origin [7, 8, [10] [11] [12] [13] , associated with therapy resistance [14] and metastatic behavior [3, 15] . TG2 is involved in tumor progression through regulation of multiple biological processes such as cell adhesion, motility, invasion, survival, and apoptosis [2] . TG2 has been shown to promote invasive ability of malignant cells by modulating the ECM and epithelial-mesenchymal transition (EMT) [16] [17] [18] . The mechanisms involved in TG2 oncogenic activity are not fully understood. Some reports have proposed activation of nuclear factor kappa β (NF-κβ) and focal adhesion kinase (FAK) [19] or downregulation of the tumor suppressor PTEN [20] . Recently, an association between TG2 expression and increased expression of transcriptional repressors Snail1, Twist, Zeb1, and Zeb2 has been found in mammary tumor cells. This mechanism promotes EMT and enhances metastatic behavior of tumor cells [18, 21, 22] . In addition, expression of TG2 is linked with activation of pathways that enrich cancer stem cells [23, 24] .
Recently, TG2 expression has been described in tumor epithelial cells [24] and in tumor stroma [25] [26] [27] [28] . In breast cancer patients, stromal TG2 expression was inversely correlated with disease-free survival [26] . Park et al. showed in renal cell carcinoma that strong epithelial TG2 expression is significantly associated with poor prognosis [29] . In colon cancer, high TG2 messenger RNA (mRNA) expression was found to be a marker of bad prognosis [30] . In contrast, TG2 downregulation in colon cancer cell lines induced higher invasiveness and aggressiveness [31] . In liver metastases of colon cancer, low expression of TG2 has been reported [31] . As TG2 is expressed in tumor stroma as well as in tumor epithelial cells, location of TG2 might have different clinical implications, but this has not been studied in human cancer. Our aim was therefore to analyze possible association of stromal and epithelial TG2 expressions with clinical data in a retrospective series of patients with colon carcinoma.
Patients and methods

Study design
A priori sample size analysis indicated that in order to obtain 90 % power with an alpha error of 0.05, 200 patients had to be selected. To evaluate TG2 expression and its association with prognosis, we randomly selected from colon carcinoma cases diagnosed in our Fundación Jiménez Díaz Hospital (Madrid, Spain) between January 2003 and December 2009 a retrospective case series of 198 patients (Supplementary Table S1 ). All patients were followed up for at least 5 years. As rectal carcinoma patients receive neoadjuvant therapy before surgery, we excluded rectal cancer cases. Demographic data were retrieved from the electronic patient files. Patients with a TNM stage I and II tumor did not receive further therapy after surgery, while those with a stage III and IV tumor received oxaliplatin-and 5-fluorouracil-based adjuvant chemotherapy. Informed written consent was obtained from all participants, as required and approved by the Research Ethics Committee of the Hospital.
Main outcome variables of the study were disease-free survival (DFS), defined as the time period elapsed between surgical therapy of the primary tumor and disease relapse (in months), and overall survival (OS), defined as the time period elapsed between primary therapy and death of disease (also in months). For DFS, we analyzed stage I, II, and III cases and for OS analysis, the whole cohort.
External dataset
For in silico analysis, we used the GSE39582 dataset, which contains a cohort of 585 patients of colon cancer. Data were transformed in z-scores and z-ratio values. Positive and negative z-ratios indicated a significantly higher, respectively, lower expression level.
Tissue samples
Tissue samples from all 198 patients were obtained from the Surgical Pathology Department (Fundación Jiménez Díaz, Madrid) and reviewed by two pathologists specialized in gastrointestinal pathology to confirm pathological stage and grade of the tumors. A tissue microarray (TMA) was constructed containing two 1-mm cores each from 172 colon cancers and 49 liver metastases (Supplementary Table S1 ).
Quantitative PCR
For quantitative PCR, we used paired normal and tumor tissue samples of 70 cases. RNA was isolated from three 10-μm sections of formalin-fixed, paraffin-embedded tissue using the BNucleoSpin totalRNA FFPE XS^Kit (MachereyNagel). As the sections contained more than 85 % of tumor, macrodissection or microdissection was not performed for mRNA extraction. cDNA was subsequently obtained using SuperScript II First Strand Synthesis System with random hexamers (Invitrogen). Real-time quantitative PCR (QPCR) was performed using the FastStart Master Mix (Roche) with probes from the Universal Probe Library Set (Roche). Amplifications were run in a LightCycler® 480 (Roche). Each value was adjusted using β-actin and 18S RNA levels as reference. Expression of the selected genes was considered positive when the tumor/normal ratio showed a value of ≥2.
Immunohistochemistry
To assess protein location within the tumor, we performed TG2 immunohistochemistry on tissue sections. Each section was deparaffinized for antigen retrieval (by microwave) using sodium citrate (pH 6.0) for 20 min and subsequently incubated with anti-TG2 antibody (1:250, ab73170; Abcam). EnVision Dual Link System-HRP (Dako) was used to visualize immunoreactivity. The reaction was developed using diaminobenzidine as chromogen and hematoxylin as a counterstain. In all cases, sections from normal colonic mucosa distant from the tumor site were used as negative controls.
All the slides were reviewed independently by two pathologists, blinded to patient outcome. Immunoreactivity was scored by assessing the percentage of cells showing cytoplasmic and/or membrane staining as well as the intensity of expression (weak [=1], moderate [=2], or intense [=3]). A QuickScore (intensity × percentage, values ranging from 0 to 300) was finally calculated. A ROC curve model was built to define the best cutoff point to classify cases as negative or positive. For both epithelial and stromal staining, the cutoff point was set at 150, allowing classification of cases as negative (<150), moderate (151-225), or intense (>225). As an example, when 50 % of the cells showed intense reactivity or 75 % of the cells showed moderately intense immunoreactivity, the score (150) would be positive. The concordance rate between the two pathologists was over 80 %. Discordant cases were jointly reviewed to achieve final agreement.
Statistical analysis
Variables used in the study are described as mean (standard deviation) or percentage, as appropriate. Associations between variables were analyzed with the chi-squared or Student's t test for comparison of means. Univariate survival analysis was investigated using Kaplan-Meier plots and compared by the log-rank test. Cox multivariate survival model was used for DFS and OS. Significance was established at p < 0.05 for all tests, while for survival, p < 0.1 was considered a trend to significance. All the analyses were performed with SPSS 20.0 for Windows.
Results
Prognostic value of TG2 mRNA expression in colon cancer
To assess associations of TG2 expression with colon cancer patient outcome, we first used the external public dataset GSE39582 (585 patients) and then qPCR. For in silico analysis, patients were divided into low expression (negative zscore) or high expression (positive z-score). Patients without distant metastasis at diagnosis and high expression of TG2 showed earlier relapse than patients with low expression (HR 1.59 [95 % CI 1.2-2.3]; log-rank test p value = 0.006) (Fig. 1a) , but no significant association was found with OS (Fig. 1b) . This association was stronger for stage II patients (HR 2.38 [95 % CI 1.4-4.1]; p value = 0.001) (Fig. 1c) .
TG2 mRNA expression was assessed in 70 paired colon cancer samples by qPCR (Supplementary Table S2 ). Females were slightly overrepresented compared to males, but cancer location was uniformly distributed between right and left colon. Most cases were stage II or III, although the cohort contained also patients with distant metastases (stage IV). High TG2 expression was found in 25 out of 70 (34 % (Fig. 1d, e) .
Prognostic value of TG2 expression according to its location
Use of whole-tissue sections without microdissection or macrodissection for mRNA extraction does not allow the distinction between stromal and epithelial expressions. To study the precise location of TG2 within the tumor, we performed immunohistochemistry (Supplementary Table S4 ). IHC analysis showed staining of stromal cells in 89 % of cases, as opposed to 61 % cases showing epithelial TG2 expression (Fig. 2a) . Stromal staining was intense to moderate, while epithelial staining was mainly moderate, with intense staining in only 11 % of the samples (Fig. 2b) . We did not find a significant association between stromal and epithelial expressions of TG2 (likelihood ratio p = 0.6).
In 49 cases, TG2 expression was analyzed by qPCR and IHC. Of 16 cases with high level of expression of TG2 mRNA, 14 (88 %) were also positive by immunohistochemistry. Of 33 cases with a low level of expression of TG2 mRNA, 15 (46 %) were negative by immunohistochemistry. This leaves 18 cases (54 %) with low mRNA expression but positivity by IHC.
By univariate statistical analysis, we found a significant association between TG2 epithelial expression, the presence of metastasis at diagnosis, and TNM stage. Low TG2 expression was associated with more advanced disease. Left (including sigmoid) colon carcinomas exhibited significantly higher TG2 stromal expression than cecum, right, and transverse colon carcinomas (Supplementary Tables S5 and S6) . No other significant associations for TG2 were found for stromal expression.
By Kaplan-Meier survival analysis, TG2 epithelial expression was not significantly associated with survival (Fig. 3a, b) , but stromal TG2 expression was associated with DFS in nonmetastatic patients (Fig. 3c, d) . To test the importance of staining intensity, positive cases were subdivided into moderate or intense. Patients with intense stromal staining showed shorter time to recurrence than TG2 stromal-negative patients. Moderate staining was associated with an intermediate risk of relapse (Fig. 3d) , also for stage II patients (Fig. 3e) . In stage IV patients (with distant metastasis at time of diagnosis), a significant association between epithelial TG2 staining and overall survival was found (Fig. 3f) . By Cox multivariate survival model, a significant and independent association between epithelial TG2 expression and OS was found (Supplementary  Table S7 ), while for stromal expression, only a trend towards significant association with DFS was observed (p < 0.1) (Supplementary Table S8 ).
TG2 expression in liver metastases
Stage I-III patients with high TG2 stromal expression showed a trend towards more frequent recurrence at 36 months than patients with low stromal TG2 expression (60 vs. 43 %; p < 0.1) (Fig. Fig. 4a ). However, no association was found between recurrence and epithelial TG2 expression (Fig. Fig. 4b ). In metastases, stromal expression was more frequent (85 %) than epithelial expression (29 %) (Fig. Fig. 4c ). TG2 stromal expression was not significantly different from that in the corresponding primary tumor (p = 0.3), while epithelial expression was less frequent than in the corresponding primary tumor (29 vs. 61 %) (Fig. Fig. 4d ). TG2 stromal expression was higher in the primary tumor of patients with liver metastasis.
Discussion
Ours is the first study to determine independent associations of stromal and epithelial expressions of TG2 with prognosis in colon carcinoma, using Bin silico^analysis, qPCR, and immunohistochemistry. We found stromal TG2 expression in 89 % of cases and epithelial expression in 61 %. Stromal expression was significantly associated with risk of relapse in stage II patients. Although up to 20 % of stage II cases relapse, cancer patients. Kaplan-Meier curves were compared with the log-rank test, and hazard ratio values were based on Cox's univariate survival model adjuvant therapy is not usually recommended for this group of patients. Finding factors which predict poor outcome is particularly important for this group of patients to decide on further therapy after surgery. We observed for the whole cohort that high TG2 expression correlates with worse prognosis in terms of DFS and OS. Epithelial expression tended to be less frequent in metastases, but stage IV patients with high epithelial TG2 expression in the metastasis showed significantly shorter survival. Our finding that expression of TG2 may be lost in a liver metastasis clarifies previous apparently conflicting reports [30, 31] . TG2 mRNA expression level by qPCR was associated with prognosis in terms of DFS and OS. This contrasts with the results of in silico analysis, which showed that in nonmetastatic patients, high TG2 expression is associated with earlier relapse but not with OS. As cause for this discrepancy, differences in definition of cases with high and low expressions between the two approaches should be considered. In the in silico analysis, this was done by comparing individual cases to the median expression level, while in the qPCR study, mRNA fold change relative to adjacent normal tissue was used.
We found good correspondence between the results of qPCR and IHC. Discrepancies between both tests might be due to the fact that qPCR is performed on whole-tissue sections, including stromal and epithelial cells. By immunohistochemistry, 89 % of patients showed high stromal TG2 expression compartment, whereas 61 % of patients showed moderate epithelial expression. High stromal expression was associated with shorter DFS, while high epithelial expression was associated with OS in stage IV patients.
In recent years, many reports have substantiated the role of tumor stroma in the development and progression of tumors [25, 32] . TG2 expression was found higher in colon cancerassociated fibroblasts (CAFs) than in normal fibroblasts [25] . CAFs acquire a phenotype similar to that of myofibroblasts in wound healing, in which TG2 is implicated and up-regulated [4] [5] [6] [7] . Fibroblasts overexpressing TG2 showed high adhesion and better extensibility [4] . Microvesicles containing TG2 shed by cancer cells are capable of conferring the transformed characteristics of a cancer cell onto normal fibroblasts and epithelial cells [33] . TG2 is up-regulated by TGFβ and promotes incorporation and activation of TGFβ into ECM [2, 34] , which might explain high TG2 expression in tumor stroma, and its association with increased risk of relapse in nonmetastatic patients. We observed high stromal expression of TG2 in liver metastases, similar to that in primary tumors. This suggests that TG2 expression in tumor stroma is required for metastatic progression of colon cancer.
TG2 induces chemoresistance by inhibiting apoptosis and autophagy, inducing EMT and favoring stemness [18, 21, 23] . Another interesting aspect of TG2 is its potential as a target for therapy. TG2 siRNA has been successfully used to reverse drug resistance in preclinical models of ovarian and pancreatic carcinomas, but clinical evidence is still scarce and further studies are needed [35, 36] . A good alternative might be the development of small-molecule inhibitors selectively targeting TG2. Such drugs have already provided promising results in inflammatory disorders [37] . In mammary tumor cell lines, enzymatically inactive TG2 is still able to effectively induce EMT and drug resistance, through activation of NF-κB and other pathways [38] . Therefore, it might be better to identify molecules that can bind TG2 and lock it in an inactive state [39] . Interestingly, the anti-oncogenic activity of cantharidine was associated with low TG2 levels in human tumor tissue samples [40] .
In conclusion, our results indicate that TG2 expression is a marker of poor outcome in colon carcinoma. High stromal expression is associated with increased relapse risk, while epithelial expression in metastatic patients is associated with poor overall survival. Potentially, TG2 expression might help Kaplan-Meier curves were compared with the log-rank test. The hazard ratio was based on Cox's univariate survival model to stratify colon cancer patients for additional therapy, but this will need further study in larger prospective series of patients. 
